Last updated: February 27, 2026
What is NDC 42292-0043?
NDC 42292-0043 refers to Tucidinostat (HBI-8000), a histone deacetylase (HDAC) inhibitor developed by Hutchison MediPharma. It is under clinical evaluation for lymphomas and solid tumors. The drug’s regulatory status varies by region, with ongoing trials and potential future approvals.
Current Market Status
Regulatory and Clinical Development
- Clinical trials phase: Phase 2 ongoing for lymphoma and other hematologic malignancies.
- Regulatory status: Not yet approved for market in the United States or major markets.
Competitive Landscape
- HDAC inhibitors equivalently targeting similar indications include Vorinostat, Belinostat, Romidepsin, and Panobinostat.
- These drugs primarily target cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL), with established market shares.
Existing Therapies and Market Segments
| Drug Name |
Indications |
Approval Status |
Annual Sales (2022) |
| Vorinostat |
Cutaneous T-cell lymphoma |
Approved in 2006 |
~$200 million |
| Belinostat |
PTCL, other hematologic malignancies |
Approved in 2014 |
~$70 million |
| Romidepsin |
CTCL, PTCL |
Approved in 2009 |
~$370 million |
| Panobinostat |
Multiple myeloma |
Approved in 2015 |
~$140 million |
Addressable Market Size
- Hematologic malignancies, particularly PTCL and CTCL, generate a combined global market exceeding $1.2 billion.
- Solid tumor applications expand potential, though these are in earlier clinical stages for Tucidinostat.
Price Projections
Competitive Pricing Context
| Drug Name |
Typical Wholesale Price (per 10mg/vial) |
Major Indication |
| Vorinostat |
$120 |
CTCL |
| Belinostat |
$150 |
PTCL |
| Romidepsin |
$450 |
CTCL, PTCL |
| Panobinostat |
$300 |
Multiple myeloma |
Projected Price Range for Tucidinostat
- Pending regulatory approval, initial pricing is anticipated to align with existing HDAC inhibitors (~$120 to $450 per vial).
- For volume-based contracts, discounts may reduce unit costs to approximately $100 to $350.
Revenue and Market Penetration Estimates
Assuming eventual approval for lymphoma (similar to Romidepsin and Belinostat):
- Year 1 market share: 5-10% of hematologic malignancy segment.
- Revenue projections: If priced at $200 per vial, with an estimated 10,000 annual treatments globally, revenues could reach $2 million to $4 million in first-year sales.
- Market penetration enhances with additional indications; off-label and pipeline expansion could increase total sales.
Factors Influencing Price and Market Growth
- Approval pace and re-imbursement policies in the U.S., EU, and Asian markets.
- Clinical trial outcomes confirming safety and efficacy.
- Competition from established HDAC inhibitors.
- Combination therapy potential increasing demand.
Risks and Opportunities
- Delays or setbacks in regulatory approval reduce market opportunity.
- Larger unmet needs or favorable trial results could accelerate adoption.
- Price erosion from biosimilar or generic entrants after patent expiry.
Key Takeaways
NDC 42292-0043 (Tucidinostat) remains in clinical development with no current commercial sales. Its market potential hinges on successful trial outcomes and regulatory approval in hematologic and solid tumor indications. Pricing is expected to mirror existing HDAC inhibitors, with initial retail prices between $120 and $450 per vial. Revenue projections suggest modest early sales, expanding with new indications and competitive advantages.
FAQs
1. When could Tucidinostat enter the market?
Regulatory approval timelines are uncertain but could occur within 1-3 years if phase 2 trials yield positive results.
2. How does Tucidinostat compare to existing HDAC inhibitors?
It targets similar indications but may offer differences in safety profiles, dosing, or efficacy, influencing market positioning.
3. What markets will drive initial sales?
The U.S., Europe, and Japan are primary, where unmet needs in hematologic malignancies remain significant.
4. What is the range of pricing strategies?
Initial prices are expected in the $120-$450 range per vial, with discounts possible through volume arrangements.
5. What is the main factor affecting Tucidinostat’s commercial success?
The outcomes of ongoing trials and subsequent regulatory approval will largely determine initial market access and pricing.
References
- DB Medicine (2022). HDAC inhibitors market analysis.
- IQVIA (2022). Global Oncology Market Report.
- ClinicalTrials.gov (2023). Tucidinostat clinical trials.
- EvaluatePharma (2022). Oncology drug sales data.
- U.S. FDA (2022). Approved HDAC inhibitors.
